01—Abstract
Summary
Summary of the 8-K filed October 18, 2024. Cited figures are marked; the original filing is the authoritative source.
CVS Health announced on October 18, 2024 that J.
David Joyner, previously EVP and President of Pharmacy Services, has been appointed President and Chief Executive Officer effective October 17, 2024, replacing Karen Lynch, who resigned as CEO and from the Board on the same day. Board Chairman Roger Farah becomes Executive Chairman, and Joyner joins the Board and its Executive Committee. The leadership change was made by the Board, which said it believed it was the right time for a change, and Joyner has 37 years of health care and pharmacy benefit management experience, including prior roles at CVS Caremark.
The more consequential news for investors is the preliminary third quarter 2024 update. The company now expects GAAP diluted EPS of $0.03 to $0.08a and Adjusted EPS of $1.05 to $1.10. Results include roughly $1.1 billion of premium deficiency reserves (PDRs), mainly in the Medicare and Individual Exchange businesses within Health Care Benefits, which reduced Adjusted EPS by $0.63 and are expected to be substantially released in Q4 2024.
GAAP results also carry a restructuring charge of about $1.2 billionb tied to closing 271 additional retail stores in 2025 and other cost reduction actions. The medical benefit ratio is expected near 95.2%, including a 220-basis-point PDR impact, and management said medical cost trends exceeded its prior outlook. Investors were told not to rely on prior guidance from the August 7, 2024 earnings call.
The full Q3 update is scheduled for November 6, 2024. For Ms. Lynch's departure, she is eligible for separation benefits under her employment agreement, and her equity awards no longer face partial-vesting limits, so she can vest in full (performance awards remain subject to performance metrics).
She will also serve as an advisor for six months at a monthly fee of $375,000c plus security services, and her non-compete and non-solicit period is extended to 30 months. These terms are notable for governance and cost analysis, though the amounts are modest relative to the company's scale.
02—Key points
Key Highlights
- CEO transition: J. David Joyner named President and CEO effective October 17, 2024, succeeding Karen Lynch, who resigned as CEO and director; Roger Farah becomes Executive Chairman.
- Preliminary Q3 2024 GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10, reflecting significant charges.
- Approximately $1.1 billion in premium deficiency reserves, primarily in Medicare and Individual Exchange businesses, reducing Q3 Adjusted EPS by $0.63; PDRs expected to be substantially released in Q4 2024.
- Approximately $1.2 billion restructuring charge tied to closing 271 additional retail stores in 2025 and cost reduction actions.
- Medical Benefit Ratio expected near 95.2% for Q3, including a 220-basis-point PDR impact, as medical cost trends exceeded prior projections.
- Prior 2024 guidance from the August 7, 2024 earnings call should no longer be relied upon, signaling a guidance reset.
- Former CEO Karen Lynch to receive a $375,000 monthly advisory fee for six months, with non-compete extended to 30 months and full equity vesting eligibility.
03—Questions
Frequently Asked Questions
Who is the new CEO of CVS Health and what is his background?
J. David Joyner, who is 60, was appointed President and CEO effective October 17, 2024. He was previously EVP and President of Pharmacy Services at CVS Health from January 2023, and earlier served as EVP of Sales and Account Services at CVS Caremark from 2011 to 2019. He has 37 years of health care and pharmacy benefit management experience and also joins the Board.
Why did CVS revise its guidance and what drove the Q3 charges?
The company said medical cost trends in the third quarter continued to exceed its prior outlook, particularly in the Health Care Benefits segment. It recorded about $1.1 billion in premium deficiency reserves, mainly for Medicare and Individual Exchange businesses, and about $1.2 billion in restructuring charges tied to store closures and cost reductions. Management told investors not to rely on prior guidance.
Are the premium deficiency reserves a permanent hit to earnings?
Not necessarily. Management expects the PDRs to be substantially released in the fourth quarter of 2024, which would benefit results in that period. The restructuring charges, however, are not described as reversible.
What are the terms of Karen Lynch's departure?
Lynch is eligible for separation benefits under her employment agreement, conditioned on a release of claims and compliance with restrictive covenants. Her outstanding equity awards no longer have partial-vesting limits, so she can vest in full, subject to performance metrics on PSUs. She will provide advisory services for six months at $375,000 per month plus security services, and her non-compete and non-solicit period is extended to 30 months.
When will investors get a full update on Q3 results?
The company plans to release its full third quarter 2024 results on its earnings call scheduled for November 6, 2024, after completing its standard quarterly close processes. The preliminary figures remain subject to change until then.
04—Continue